Latest Conference Articles
Researchers Explore Approaches to Block T-Cell Exhaustion
September 28th 2022, 6:35pm
Expert discusses whether epigenetic programs regulate human T cell exhaustion and whether epigenetic-based strategies can be used to enhance T cell-based therapies.
Researchers Tackle Limitations, Opportunities of CAR T Cells in Solid Tumors
September 28th 2022, 1:53pm
New research has shown significant promise for the use of CAR T-cell therapies in solid tumors.
NIH Explores New Field of Liberation Data Science in All of Us Research Program
September 22nd 2022, 2:19pm
The All of Us Research Program looks to enroll more than 1 million US individuals in the next 10 years to enable public access to medical data for research purposes.
Neighborhood Adversity Associated With Increased Risk of ER- Breast Cancer, TNBC for Black Women in the United States
September 21st 2022, 5:35pm
Data showed that Black women, regardless of education level or income, are more likely to reside in disadvantaged neighborhoods, which may contribute to racial disparities in breast cancer.
US Residents of Mexican Descent Show Higher Liver Cancer Risk in Successive Generations
September 20th 2022, 5:07pm
Second- and third-generation individuals living in Los Angeles, California, demonstrate 35% and 61%, respectively, more of a chance of getting the disease, according to new study results.
Cabozantinib, Nivolumab, Ipilimumab Combination Does Not Reach PFS
September 15th 2022, 1:30pm
Triplet combination demonstrates a reduction in the risk of disease progression or death in individuals with previously untreated advanced intermediate- or poor-risk renal cell carcinoma.
Mirati Releases Promising Adagrasib Results for Advanced Colorectal Cancer
September 14th 2022, 5:35pm
Therapy shows positive clinical efficacy and favorable tolerability as a monotherapy and in combination with cetuximab in heavily pretreated patients who have a KRASG12C mutation.
Study: Fianlimab With Cemiplimab Combination Shows High Response Rate in Certain Patients With Advanced Melanoma
September 14th 2022, 4:59pm
New research presented at ESMO Congress found that certain patients with advanced melanoma administered a combination of cemiplimab with fianlimab experienced a median progression-free survival of 2 years.
Osimertinib Significantly Improves Disease-Free Survival in EGFR-Mutated Lung Cancer
September 14th 2022, 2:25pm
Researchers at the European Society for Medical Oncology Congress presented findings that show osimertinib may clinically reduce the risk of lung cancer recurrence.
Trastuzumab Deruxtecan Shows Clinically Meaningful Response in Non-Small Cell Lung Cancer
September 13th 2022, 6:07pm
Trastuzumab deruxtecan produces a confirmed objective response rate of 53.8% and 42.9% in the 5.4 mg/kg arm and 6.4 mg/kg treatment arms, respectively, among patients with HER2 mutant non-small cell lung cancer.